In a recent SEC filing, Baillie Gifford revealed a substantial increase in its holdings of Edwards Lifesciences (EW) during the second quarter of 2026. The investment firm boosted its position by over 174%, bringing its total ownership to 1.21 million shares valued at approximately $109.36 million as of June 30. This disclosure comes from a mandatory 13F filing, which reports positions held at the end of a quarter and is therefore a delayed look at the firm's portfolio changes.
In a quarterly report for its Positive Change strategy, Baillie Gifford stated it initiated the position due to what it saw as an attractive entry point following share price weakness. The firm believes the medical device company's valuation does not fully reflect its long-term growth opportunities in minimally invasive heart therapies. The activity preceded Edwards Lifesciences' strong second-quarter earnings report in late July, where it raised its sales guidance for the full year.